Nexstim reports promising clinical outcomes of first 55 patients completing SmartFocus® rTMS treatment of Major Depressive Disorder
Helsinki, Finland: 17 April 2020 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) reports the clinical outcomes of the first 55 patients who have completed SmartFocus® rTMS therapy for treatment of major depressive disorder (MDD) at clinical sites in the United States.
40% of the patients completing the treatment achieved clinical remission and 71% obtained a clinical response at the end of treatment.
These outcomes are higher than what is usually reported for MDD: In a well-conducted multisite study, the patient-reported remission rates were 26.5-28.7 % and response rates were 41.5-56.4 %1).
The clinical outcomes of SmartFocus® rTMS treated patients are being collected in a registry — the information is provided by participating clinical sites using Nexstim’s SmartFocus® technology. The results are based on the patient reported outcome measures on Beck’s Depression Inventory (BDI) and Patient Health Questionnaire -9 (PHQ-9), which are two frequently used instruments to measure depression severity.
According to the registry data, the patients also reported that the experience of receiving the treatment was generally very positive as reflected by a mean score of 8.7 on a scale of 0 to 10.
Further information on Nexstim’s website.